Diabetes mellitus is indeed one of the most difficult to treat syndromes – at the same time, many scientists in the world are actively struggling to develop a more or less universal therapy format for most diabetics. So there was news about the similar achievement of specialists from the University of California, who were previously approved to conduct preliminary tests on patients suffering from type 1 diabetes or those who are very close to it – of course, with the consent of the patients themselves. This is a new experimental drug called Teplizumab.
This drug was developed as a kind of mixing several drugs, whose main goal is to keep the development of symptoms of diabetes mellitus of the first type – which in turn allows doctors to more effectively identify and neutralize the original cause of the circulatory condition. Diabetes mellitus of the first type is characterized by the inability to consume glucose by the cells themselves, although they can decompose carbohydrates.
Thus, the presented medicine really allowed many of the patients to experience a marked relief when taken, while statistically it helped to reduce the diagnosis of type 1 diabetes mellitus to 60% in 55 children and in 21 adult patients. This means that the substance was able to neutralize in time the main reason for the inability of the cell to process and absorb glucose. Moreover, during the second stage of testing with the use of this drug, it was found that it can significantly slow down post-diabetic symptoms.
And this makes it possible in a real situation to delay their development and deterioration, thereby allowing the attending physician to determine the most accurate range of causes that may lead to further post-diabetic condition. However, for now it remains to wait for the final results of the presented research and hope that the new drug is really effective.